Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sign Test for Matched Pairs01:17

Sign Test for Matched Pairs

425
The sign test for matched pairs offers a robust method for comparing two paired samples, often for the effects of an intervention in one of them. This method is very useful in situations where the underlying distribution of the data is unknown. The test compares two related samples—often pre- and post-treatment measurements on the same subjects—to determine if there are significant differences in their median values.
To conduct the sign test, we first calculate the differences in...
425
Feedback Inhibition00:46

Feedback Inhibition

57.3K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.3K
Relative Risk01:12

Relative Risk

2.2K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.2K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.6K
Wilcoxon Signed-Ranks Test for Matched Pairs01:09

Wilcoxon Signed-Ranks Test for Matched Pairs

504
The Wilcoxon signed-rank test for matched pairs evaluates the null hypothesis by combining the ranks of differences with their signs. It essentially tests whether the median of the differences in a population of matched pairs is zero. Since the test incorporates more information than the sign test, it generally yields more trustable conclusions. This test also does not require the data to follow a normal distribution, but two conditions must be met for it to be applicable: (1) the data must...
504
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

13.8K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term comparative efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and chronic kidney disease: A nationwide observational study.

Heart rhythm·2026
Same author

The Safety Profile of Ticagrelor Among Older Adults (age ≥ 75 years): A Pharmacovigilance Analysis.

Cardiology·2026
Same author

Increased risk of atrial fibrillation and flutter in patients with Cushing's syndrome: a population-based matched cohort study.

European journal of endocrinology·2026
Same author

Real-World Outcomes of FFRangio-Guided Treatment for Coronary Artery Disease in Acute Versus Chronic Coronary Syndromes.

Journal of the American Heart Association·2026
Same author

Associations of 10-year predicted ASCVD risk by the PREVENT equations with AI-analyzed coronary atherosclerotic plaque characteristics.

American journal of preventive cardiology·2026
Same author

Dynamic Changes in Circulating Osteogenic Progenitor Cells Following TAVI: Implications for Vascular Remodeling-EPC and EPC-OCN Dynamics After TAVI.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Feb 11, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large

Inbar Nardi Agmon1,2,3,4, Chen Gurevitz1,2, Tzippy Shochat5

  • 1Division of Cardiology, Rabin Medical Center, Petach Tikva, Israel.

Clinical Pharmacology and Therapeutics
|February 10, 2026
PubMed
Summary
This summary is machine-generated.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) show no overall increased cancer risk and reduce mortality. Men on PCSK9 mAbs had a slightly higher cancer incidence, possibly due to baseline factors.

More Related Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.6K
Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
09:36

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats

Published on: October 16, 2010

30.3K

Related Experiment Videos

Last Updated: Feb 11, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.6K
Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
09:36

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats

Published on: October 16, 2010

30.3K

Area of Science:

  • Cardiovascular Medicine
  • Oncology
  • Immunology

Background:

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) effectively lower LDL cholesterol.
  • PCSK9 mAbs may influence cancer via immunomodulatory pathways, but their impact on human cancer incidence is unknown.

Purpose of the Study:

  • To investigate the effect of PCSK9 mAbs on human cancer incidence compared to ezetimibe.
  • To assess the association of PCSK9 mAbs with all-cause mortality.

Main Methods:

  • Retrospective, propensity score-matched study of 9,876 patients (2,469 PCSK9 mAb, 7,407 ezetimibe) from Clalit Health Services (2010-2023).
  • Patients received treatment for ≥6 months, with a 1-year latency period applied. Analysis included sex-stratification.

Main Results:

  • Overall cancer incidence was similar between PCSK9 mAb users (12%) and ezetimibe users (11%) (HR 1.09).
  • Men on PCSK9 mAbs showed a higher cancer incidence (12.5% vs. 10.3%, P=0.03), while women showed no difference.
  • All-cause mortality was significantly lower in the PCSK9 mAb group (3% vs. 5%; HR 0.65).

Conclusions:

  • PCSK9 mAb therapy appears safe concerning overall cancer risk.
  • PCSK9 mAbs are associated with a significant reduction in all-cause mortality.
  • The observed higher cancer incidence in men may be linked to baseline risk factor prevalence.